Tato stránka byla automaticky přeložena a přesnost překladu není zaručena. Podívejte se prosím na anglická verze pro zdrojový text.

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants (PNIRS in VLBWI)

17. listopadu 2026 aktualizováno: Lizelle Van Wyk, University of Stellenbosch

Pulmonary Near-infrared Spectroscopy to Predict the Need for Surfactant in Very Low Birth Weight Infants: a Pilot Study

This study will look at whether a monitoring method called near-infrared spectroscopy (NIRS), can help assess lung disease in premature babies.

The main aim of this study is to describe lung oxygen levels measured by NIRS in premature babies with respiratory distress syndrome (RDS) during the first 72 hours after birth. The study will include babies born at or before 32 weeks of pregnancy who need continuous positive airway pressure (CPAP) for RDS. The study will also assess whether these lung oxygen measurements can help predict which babies will need surfactant treatment, and whether they can predict which babies may need more than one dose of surfactant.

The study will also compare lung NIRS measurements with other ways of assessing breathing problems, including lung ultrasound scores and oxygen-related measurements. In addition, the researchers will compare lung oxygen measurements with brain oxygen measurements. They will also look at whether surfactant treatment changes oxygen levels in the lungs and brain. Information from routine vital signs, such as heart rate, breathing rate, and oxygen saturation, will also be studied to see whether these measurements can help predict the need for surfactant.

Added to this researchers will look at the hemodynamics of surfactant administration by seeing how the heart and blood vessels react to surfactant administration

Přehled studie

Detailní popis

Aim: To determine pulmonary regional oxygen saturation (prSO2) in preterm infants (≤32 weeks) with respiratory distress syndrome (RDS) requiring continuous positive airway pressure (CPAP) with or without surfactant replacement therapy (SRT)

Objectives:

Primary: Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life. Secondary: (1) Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS, (2) Evaluate the ability of prSO2 to predict the need for repeat surfactant administration in preterm infants with RDS, (3) Determine correlation between prSO2, lung ultrasound (LUS) scores and oxygenation indices.

Tertiary: (1) Determine the correlation between prSO2 and cerebral oxygenation (crSO2), (2) Determine the effect of surfactant administration on prSO2 and crSO2, (3) longitudinal analyses of vital signs (HR, SpO2, NIRS, oxygenation indices) to predict SRT, (4) determine the hemodynamic effects of SRT (longitudinal correlation of NIRS, haemodynamic parameters)

This will be an investigator-initiated, prospective, observational trial.

Preterm infants born at a gestational age ≤ 32 weeks will be recruited from a single neonatal center, Tygerberg Hospital, Cape Town, South Africa.

All preterm infants ≤ 32 weeks and/ or ≤1800g will be eligible for enrollment

Study Procedures

Recruitment and enrollment processes Infants will be screened within the first 3 hours after birth. Infants meeting enrollment criteria will be placed on study monitoring devices upon arrival in the neonatal unit, if meeting eligibility criteria.

Randomization/ blinding No randomization will occur in this study. Blinding is not possible due to visible monitoring equipment. Treating clinicians will however be directed not to use the monitors for any decision-making regarding patient management.

Monitoring Devices

  1. Near-infrared spectroscopy will be performed using INVOS 5100c (Medtronics, Minneapolis, MN, USA) with 2 transducers, will be used that allows monitoring of 4 regions of interest. In this study 3 regional saturations will be monitored - pulmonary (left and right) and cerebral

    • Pulmonary NIRS - Pulmonary sensors will be placed in a horizontal position at the 4th intercostal space area (nipple line) on the left and right hemithorax
    • Cerebral NIRS - Cerebral sensor will be placed on the right of the forehead
  2. Vital sign monitoring: Synchronized vital signs (heart rate (HR), respiratory rate (RR), peripheral oxygen saturation (SpO2) (Nellcor) will be monitored using a multi-parameter monitor (Mindray UMEC15, Shenzhen, China).

  3. Non-invasive cardiac output monitoring: Haemodynamic monitoring will occur using the ICON Core from Osypka Medical. This provides non-invasive monitoring of numerous haemodynamic parameters, including cardiac output, stroke volume, systemic vascular resistance, cardiac contractility and thoracic fluid content. ICON sensors will be placed in standard positions on the forehead, neck arm and leg for monitoring.

Intervention procedures

1. Ultrasound:

  1. Lung ultrasound (LUS) will be performed after placement of the NIRS (within the first 6 hours of life) and daily. LUS will also be performed prior to any SRT. alculated. Video-clips will be stored and reviewed by blinded co-investigators.
  2. Cranial ultrasound (CUS) will be performed on day 1,2 and 3 to monitor for any intraventricular haemorrhage as well as to measure cerebral blood flow velocities, which may affect crSO2 values.
  3. Point-of-care echocardiography (POC-echo) will be performed to determine cardiac function, cardiac output, and the presence of a patent ductus arteriosus, size, flow velocity and pattern, which may affect prSO2 and crSO2 values. Standard echocardiography techniques will be used and will be performed daily on day 1,2 and 3 of life.

Trial duration

The trial will start enrolling 1 November 2026 or when all procedures have been completed. Trial will be completed when 100 participants have been recruited.

Discontinuation of study intervention

Monitoring of the infant will stop, and sensors will be removed if:

  • Requested by mother
  • Requested by treating clinician
  • Thoracic intervention required (e.g. intercostal drainage for pneumothorax)
  • Surgery required (e.g. laparotomy for focal intestinal perforation)
  • Sensors interfere with medical management

Withdrawal from study

At any time point the mother or treating clinician may request withdrawal of the infant from the study, for any reason, whether for personal choice (by the mother), safety considerations or administrative reasons. Monitoring of the infant will be stopped immediately, and no further data will be collected. However, the infant will remain in the study for data analyses and outcome and clinical measure collection, unless the mother specifically requests that their infant's data not be included. Withdrawal of the infant from the study, irrespective of reason, will not influence the continued management of the infant and they will continue to receive management as per protocols in the institution.

Duration of study participation

Study participation for each infant is:

  • Initiated within the first 3 hours of life
  • Monitoring until 72 hours after birth
  • Follow up from 72 hours until final discharge from hospital or in-hospital death.

Infants who are transferred to other institutions will be followed up for length of stay as well as neonatal respiratory complications (length of respiratory support, bronchopulmonary dysplasia, death)

Typ studie

Pozorovací

Zápis (Odhadovaný)

100

Kontakty a umístění

Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.

Studijní kontakt

  • Jméno: Lizelle Van Wyk, PhD
  • Telefonní číslo: +27219389506
  • E-mail: lizelle@sun.ac.za

Studijní místa

      • Cape Town, Jižní Afrika, 7530
        • Nábor
        • Tygerberg Hospital
        • Kontakt:
          • Lizelle Van Wyk, PhD
          • Telefonní číslo: 6058 +27219384911
          • E-mail: lizelle@sun.ac.za
        • Kontakt:
          • Pierre Goussard, PhD
          • Telefonní číslo: +27219389506
          • E-mail: pgouss@sun.ac.za
        • Vrchní vyšetřovatel:
          • Lizelle Van Wyk, PhD
        • Dílčí vyšetřovatel:
          • Pierre Goussard, PhD

Kritéria účasti

Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.

Kritéria způsobilosti

Věk způsobilý ke studiu

6 měsíců až 7 měsíců (Dítě)

Přijímá zdravé dobrovolníky

Ne

Pohlaví způsobilá ke studiu

Všechno

Metoda odběru vzorků

Vzorek nepravděpodobnosti

Studijní populace

All preterm infants 27-32 weeks born at Tygerberg Hospital, Cape Town, South Africa will be elligible for enrollment

Popis

Inclusion Criteria:

  • Preterm infant ≤ 32 weeks gestational age and/ or birth weight ≤ 1800g
  • Infant diagnosed with respiratory distress syndrome requiring CPAP after birth
  • Infant born at the research institution

Exclusion Criteria:

  • Infants ≤ 26 weeks gestational age or <750g
  • Infants with other causes of respiratory distress
  • Infants with antenatal or postnatally diagnosed structural pulmonary abnormalities
  • Infants with known or suspected chromosomal abnormalities
  • Infants with other congenital structural abnormalities that may require surgery in the first 72 hours after birth
  • Infants with known or suspected congenital infections including congenital syphilis, cytomegalovirus or toxoplasmosis
  • Infants intubated after birth or requiring intubation and invasive ventilation immediately after birth
  • Infants with a 5-minute Apgar ≤ 5
  • Instillation of surfactant prior to enrollment
  • Infants not expected to survive the first 72 hours after birth

Studijní plán

Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.

Jak je studie koncipována?

Detaily designu

  • Observační modely: COHORT
  • Časové perspektivy: PROSPECTIVE

Kohorty a intervence

Skupina / kohorta
Intervence / Léčba
CPAP only

Infants receiving CPAP only

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

SRT

Infants receiving CPAP plus surfactant

Pulmonary near-infrared spectroscopy sensors will be placed in a horizontal position

Co je měření studie?

Primární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
PRSO2 values
Časové okno: 72 hours

Determine longitudinal prSO2 values for infants with RDS during first 72 hours of life

72 hours

Sekundární výstupní opatření

Měření výsledku
Popis opatření
Časové okno
SRT prediction
Časové okno: 72 hours

Evaluate the ability of prSO2 to predict the need for surfactant administration in preterm infants with RDS

72 hours
Compare prSo2 & lung ultrasound between groups
Časové okno: 72 hours

Determine correlation between prSO2 and lung ultrasound (LUS) scores between groups

72 hours
Compare prSo2 & OSI between groups
Časové okno: 72 hours

Determine correlation between prSO2 and OSI between groups

72 hours
Compare prSo2 & SOPI between groups
Časové okno: 72hrs

Determine correlation between prSO2 and SOPI between groups

72hrs

Další výstupní opatření

Měření výsledku
Popis opatření
Časové okno
PRSO2/CUS
Časové okno: 72hours

Determine the correlation between prSO2 and cerebral oxygenation (crSO2) between groups

72hours
Longitudinal analysis SOPI
Časové okno: 72 hours

longitudinal comparison of SOPI between groups

72 hours
Longitudinal OSI
Časové okno: 72 hours

longitudinal comparison of OSI between groups

72 hours
Longitudinal thoracic fluid content (TFC)
Časové okno: 72 hours

longitudinal comparison of TFC between groups

72 hours
Longitudinal CI
Časové okno: 72 hours

longitudinal comparison of cardiac index between groups

72 hours

Spolupracovníci a vyšetřovatelé

Zde najdete lidi a organizace zapojené do této studie.

Spolupracovníci

Publikace a užitečné odkazy

Osoba odpovědná za zadávání informací o studiu tyto publikace poskytuje dobrovolně. Mohou se týkat čehokoli, co souvisí se studiem.

Termíny studijních záznamů

Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.

Hlavní termíny studia

Začátek studia (Odhadovaný)

1. prosince 2026

Primární dokončení (Odhadovaný)

30. prosince 2027

Dokončení studie (Odhadovaný)

31. prosince 2027

Termíny zápisu do studia

První předloženo

13. května 2026

První předloženo, které splnilo kritéria kontroly kvality

17. listopadu 2026

První zveřejněno (Aktuální)

20. listopadu 2026

Aktualizace studijních záznamů

Poslední zveřejněná aktualizace (Aktuální)

20. listopadu 2026

Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality

17. listopadu 2026

Naposledy ověřeno

1. listopadu 2026

Více informací

Termíny související s touto studií

Plán pro data jednotlivých účastníků (IPD)

Plánujete sdílet data jednotlivých účastníků (IPD)?

NE

Popis plánu IPD

Patient data, as per SUN HREC guidelines, can only be shared upon an agreed upon data sharing agreement

Informace o lécích a zařízeních, studijní dokumenty

Studuje lékový produkt regulovaný americkým FDA

Ne

Studuje produkt zařízení regulovaný americkým úřadem FDA

Ne

Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .

Předplatit